- Home
- ALDX vs DMAC Comparison
ALDX vs DMAC Comparison
Compare ALDX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- DMAC
- Stock Information
- Founded
- ALDX 2004
- DMAC 2000
- Country
- ALDX United States
- DMAC United States
- Employees
- ALDX N/A
- DMAC N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- DMAC Health Care
- Exchange
- ALDX Nasdaq
- DMAC Nasdaq
- Market Cap
- ALDX 160.8M
- DMAC 178.0M
- IPO Year
- ALDX 2014
- DMAC N/A
- Fundamental
- Price
- ALDX $3.05
- DMAC $3.63
- Analyst Decision
- ALDX Strong Buy
- DMAC Strong Buy
- Analyst Count
- ALDX 2
- DMAC 2
- Target Price
- ALDX $9.50
- DMAC $8.00
- AVG Volume (30 Days)
- ALDX 769.8K
- DMAC 110.0K
- Earning Date
- ALDX 07-31-2025
- DMAC 08-06-2025
- Dividend Yield
- ALDX N/A
- DMAC N/A
- EPS Growth
- ALDX N/A
- DMAC N/A
- EPS
- ALDX N/A
- DMAC N/A
- Revenue
- ALDX N/A
- DMAC N/A
- Revenue This Year
- ALDX N/A
- DMAC N/A
- Revenue Next Year
- ALDX N/A
- DMAC N/A
- P/E Ratio
- ALDX N/A
- DMAC N/A
- Revenue Growth
- ALDX N/A
- DMAC N/A
- 52 Week Low
- ALDX $1.14
- DMAC $2.14
- 52 Week High
- ALDX $7.20
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ALDX 61.89
- DMAC 46.56
- Support Level
- ALDX $2.60
- DMAC $4.02
- Resistance Level
- ALDX $3.24
- DMAC $4.17
- Average True Range (ATR)
- ALDX 0.22
- DMAC 0.25
- MACD
- ALDX 0.09
- DMAC -0.04
- Stochastic Oscillator
- ALDX 80.93
- DMAC 37.89
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.